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Summary: In plasma and urine of 10 healthy volunteers 
after intravenous administration of 4 g mezlocillin and pi-
peracillin, respectively, the parent compounds as well as 
degradation products were assayed by high-performance li-
quid chromatography. Ioxitalamic acid, a renal contrast me-
dium, was administered simultaneously, in order to measure 
the glomerular filtration rate, and to control the collection of 
24-h urine. As metabolite of mezlocillin the corresponding 
penicilloic acid only was found, whereas in the case of piper-
acillin a further degradation product was observed. Half of 
the doses given was recovered in the urine as unchanged 
drugs, and in addition 5-10% as metabolites. No differences 
were found in the pharmacokinetic behaviour of both anti-
biotics. 
Zusammenfassung: Hochdruckflüssigkeitschromatographi-
sche Bestimmung von Mezlocillin, Piperacillin, ihrer Abbau-
produkte und von loxitalaminsäure im Plasma und Urin ge-
sunder Probanden 
Nach intravenöser Applikation von je 4 g Mezlocillin bzw. 
Piperacillin wurden mit Hilfe der Hochdruckflüssigkeits-
chromatograpihie die Muttersubstanzen sowie Abbaupro-
dukte dieser Ureidopenicilline im Plasma und Urin von 10 
freiwilligen Prcobanden bestimmt. Um die Nierenfunktion zu 
überprüfen unid die vollständige Urinsammlung über 24 h zu 
kontrollieren, (erhielten die Versuchspersonen simultan loxi-
talaminsäure, ein Kontrastmittel, infundiert. Als einziger 
Metabolit vom Mezlocillin wurden geringe Mengen der 
entsprechendem Penicilloinsäure gefunden. Im Falle von Pi-
peracillin wuirde ein weiteres Abbauprodukt beobachtet. 
Etwa die Hälfte der gegebenen Antibiotika-Dosen wurde un-
verändert im Urin wiedergefunden, zusätzlich noch 5-10% 
in Form von Abbauprodukten. Bei den pharmakokineti-
schen Parametern beider Penicilline wurden keine signifi-
kanten Untersschiede festgestellt. 
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1. Introduction 
Mezloc i l l in (6-[D-2-(2-oxo-3-mesylimidazolidine-1 -carbox-
amido)-2-phenylacetamido]penicillanic acid) and piperacil-
l in (6-[D(-)-a-(4-ethyl-2,3-dioxo-l-piperazinyl-carbonyl-ami-
no)-2-phenylacetamido] penicillanic acid) are acylureido 
penicillins with broad antibacterial activity and with only 
slight differences between their structures (Scheme 1). Peni-
cillins are in general partially metabolized, mainly to 
inactive penicilloic acids [1]. This also was shown for mezlo-
c i l l in , but in vitro degradation of mezlocil l in in plasma 
specimens may have influenced some results, leading to false 
high concentrations of mezlocil l in penicilloic acids [3]. So 
far, no metabolites of piperacill in have been detected in 
plasma, though some inactive degradation products have 
been observed in urine and bile [2]. 
and 188 cm (miedian 174 cm). The health o f the volunteers was 
established fromi their medical history, physical examination and la-
boratory screeniing (differential blood count, platelet count, serum 
creatinine, S G O ) T , S G P T , G G T and urine analysis). N o subject was 
hypersensitive tco penici l l ins or contrast media. Pregnancy was ex-
cluded by the retgular use of contraceptives. 
2.2. Administration of antibiotics 
After giving infformed written consent the subjects received 4 g of 
mezloci l l in and after 6 weeks 4 g of piperaci l l in. Concurrently, the 
subjects receivecd 5 ml Telebrix 300®, equivalent to 2.4 g ioxitalamic 
acid, as an inteirnal standard for comparison o f the two antibiotics. 
The injection o f this contrast medium allows to measure the renal 
function as glormerular filtration rate, and to control the collection of 
the 24-h urine. The antibiotics and ioxitalamic acid were dissolved 
together in 50 ml water for injections and infused intravenously 
within 30 min ait a constant rate. 
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Scheme 1: Chemica l structures of mezloc i l l in , p iperaci l l in , and degradation p roduc t s . 
The aim of the present study was to establish the pharmaco-
kinetics of mezlocill in and piperacillin after intravenous in -
fusion of 4 g over 30 min, and to quantify their probable 
main metabolites, the corresponding penicilloic acids. For 
analysis a liquid chromatographic method was chosen in -
stead of bioassay, because these ring-open penici l l in deriva-
tives are not antibacterially active. Care was taken with the 
sampling and storage of plasma samples because of in vitro 
instability of mezlocill in and other penicillins in body fluids 
[3]. 
2. Material and methods 
2.1. Subjects 
The study included 10 healthy subjects (5 male, 5 female, aged be-
tween 22 and 34 years, median 29 years). Their weights ranged be-
tween 50 and 86 kg (median 66 kg), and their heights between 154 
2.3. Blood and murine collections for assay 
Venous blood ssamples (6 to 8 ml) were withdrawn into heparinized 
syringes from a. contralateral arm vein through an indwelling needle 
before and at specif ied intervals after infusion. These samples were 
taken at 15 mim after start of the infusion, at the end of infusion and 
at 10, 20, 30, 4:5, 60, 90 min , 2, 3, 4, 6 and 8 hours thereafter. Blood 
samples were ccentrifuged at 4 °C within 30 min and the plasma was 
stored at -70 ° C unti l analysis. Ur ine samples were collected before 
the start of the experiments and during the periods 0 to 4.5, 4.5 to 
8.5, 8.5 to 12.55, and 12.5 to 24.5 h after the start of infusion. The 
p H (ranging f r o m 5.0 to 6.5) and volumes of all urine samples were 
measured, and the specimens were stored at - 7 0 °C. The excretion 
of creatinine im the fractionated urine collections over 24 h was as-
sayed by the auitoanalyser modification of the method of JafTe (4). 
2.4. Chromatographic assay 
2.4.1. Reagents* and chemicals 
Mezloc i l l in witth the respective penicilloic acid and penilloic acid, 
piperacillin wiith its penicil loic acid and ioxitalamic acid (5-acet-
amido-N-(2-hydroxy-ethyl)-2,4,6-tr i iodo isophtalamic acid) were 
supplied by the respejctive manufacturers. A s diagrnostic agent rrueg-
lumine ioxitalamate (Telebrix 3O0®; manufacturer: Byk G u l d e n , 
Konstanz, F R Germainy)) was used.. Acetonitri le ( H P L C grade S) was 
purchased from Zinsser, F rankfu r t /Ma in (FR Germany) , tetrabutyl-
ammonium hydrogensuLfate from Fluka , N e u U l m (FR Germany). 
A l l other chemicals (;anaJytical grade) were obtained from E. M e r c k , 
Darmstadt (FR Germany) . Water was purified w i t h a M i l l i - Q water 
purification system (Mi lL ipore , Eschborn, F R Germiany). 
Stock solutions of the antibiotics, their metabolites and of iox i ta l -
amic acid were prepared in waiter to yield finail concentrations 
of 1 mg/ml , and stored in aliquots at - 2 0 °C. T h e stock solutions 
were than diluted w i t h drug-free plasma to provide assay standards 
of 50 / ig /ml for mez: loci l l in and piperaci l l in and 2 0 / ig /ml for the 
penicil loic acids of both penic i l l ins . For checking the linearity of the 
assay dilutions of 10O-0.78 ^g/ 'ml for mezloc i l l in amd piperaci l l in in 
plasma and 20-0.63 /ig/ 'ml for mez loc i l l in pen ic i l l o i c acid were pre-
pared. Lack o f sufficient material did not a l low to prepare a stand-
ard series of p iperac i l l in penicilBoic acid. For uirine samples the 
standard solutions were prepared in 50 mmol/1 sodium phosphate 
buffer (pH 6.5). 
2.4.2. Sample treatment 
Plasma samples were treated according to a publislhed procedure [5] 
with minor modifications. In brief, 200 p\ plasrma were buffered 
with 200 ß\ 50 mmol/1 sodium phosphate ( p H 6.(3) and deprotein-
ized with 400 ß\ acetonitri le. The latter was than extracted into 2 ml 
dichloromethane, amd 10 -20 iA of the aqueous phase, containing 
the penicillins and their metabolites, were injected into the Chroma-
tograph. Ur ine was centrifuged and diluted tenfold with 50 mmol/1 
sodium phosphate buffer ( p H 6.5). A l l b io logica l samples were 
stored at - 7 0 °C (up to 7 weeks) and thawed in iced water just pr ior 
to analysis. 
2.4.3. Chromatography 
The chromatographic system consisted of a pump M 6000A, an au-
tomatic injector W I S P 710B (fitted with a coo l i ng kit, in order to 
maintain 8 °C for the samples), a R C S S compression module 
equipped with a cartridge (100 x 5 m m I.D.) packed with Novapak® 
C-18 4 -5 ßm silica, a fixed-wavetlength detector M 441, a data mo-
dule M 730 and a system controller M 720 (all fromi Waters Assoc. , 
Eschborn, F R Germany) . 
The flow rate was maintained at 1.0 m l / m i n . the resulting back-
pressure was 6000 k P a . The eluent was moni tored at 214 nm (Zn-
lamp) for the determination of mez loc i l l in and at 2129 nm (Cd-lamp) 
for the determination o f p iperaci l l in . For mez loc i l l i n analysis the 
mobile phase was prepared by combining 760 m l o f 12.5 m m o l / l so-
d ium phosphate buffer (pH 6.8), 240 ml acetoniitrile and 150 mg 
tetrabutylammonium hydrogen sulfate. The appairent p H was ad-
justed to 7.3 with 10 N sodium hydroxide. Part o f the mezloc i l l in 
samples was analysed using a HIBAR® co lumn ( 1 2 5 x 4 m m I.D.) 
filled with LiChrospher® RP-18 5 ^ m sil ica (E. N4erck; for mobile 
phase composition see F i g . 1). F o r piperaci l l in assay 1 g tetrabutyl-
ammonium hydrogen sulfate was used and the p H adjusted to 6.5. 
For determination o f ioxi ta lamic acid a H I B A R column ( 1 2 5 x 4 
m m I.D.), prepacked with LiChrosorb® R P - 1 8 5 / i m silica (E. 
Merck), was used for separation. The flow rate was maintained at 
1.0 mi/min, the back-pressure was 11000 kPa . T h e mobile phase 
was a mixture of 910 m l water, 90 ml acetonitri le, 600 /u\ acetic 
acid, 350 mg te t rabutylammonium hydrogen sulfiate. The p H was 
adjusted to 4.8 with 10 N sodium hydroxide. The eluent was mon i -
tored at 254 nm (Hg-lamp), the retention time olf ioxitalamic acid 
was about 4.5 min. 
2.4.4. Pharmacokinetic analysis 
Plasma level data were analysed by the open, two-compartment mo-
del. Tne decline in drug, plasma levels in the postimfusion phase was 
fitted by a computer program for each subject us ing an iterative rela-
tive least-squares regression analysis. A Fortran program was used in 
the computation. The basic equation of the mathematical model 
was 
Cj> = A • e-*1 + B • ,-ßt 
where Op represents the plasma concentrations att time t after the 
dose. 2 and ß (mim 1 ) are hybrid constants of the fast and the s low 
disposition process, respectively, and A and B (mig/1) are the zero-
time intercepts of the two components of the biex.ponential curves. 
The calculated pharmacokinetic constants were corrected for infu-
sion t me [6]. A number of parameters have been calculated, espe-
cially following: area under the plasma concentiration-time curve 
(AUG).«,): apparent steady-state volume of distr ibut ion (V$s), total 
body :learance (C l l 0 t ) , and terminal plasma half-life* (U/iß)-
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Fig. 1: Chromatograms of (1) an aqueous standard solution of mezloci l l in 
( M E Z , 100 ng) mezloc i l l in penic i l lo ic acid ( M P C : 84 ng mixture of epimers A 
and B), and mezloc i l l in penil loic acid ( M P L ; 150 ng mixture of epimers A 
and B), (2) a plasma blank and (3) plasma o f a volunteer 4 h after intravenous 
injection (3 min) o f 5 g mezloc i l l in . The asterisk (*) marks a i unidentified 
substance that appears in treated plasma or aqueous samples, a i d disappears 
within 2 days at room temperature (see chromatogram 2). Concentrations: 
M E Z = 15 / /g /ml . M P C = 2.5 ^ g / m l . A U = absorption units. 
Chromatographic condit ions: C o l u m n : H I B A R LiChrospher RP-18 5 ^ m ; 
(125 x 4 m m I.D.); mobile phase: 2,8 g sodium dihydrogen phcsphate mono-
hydrate, 255 mg tetrabutylammonium hydrogen sulfate, 750 ~nl water, 250 
ml acetonitrile, apparent p H 6.2: flow rate: 1 m l / m i n ; pressure 11000 kPa . 
3. Results 
3.1. Chromatography 
In Fig. 1 chromatograms of a standard mixture of mezlocil-
l in and its degradation products, mezlocil l in pen ci l loic and 
penilloic acid, and of extracted human plasma are depicted. 
Each mezlocil l in metabolite elutes as two distinct peaks be-
cause of epimerization at the carbon atom in position 5 (see 
Scheme 1) [7]. The earlier eluting isomers A are the minor 
components in freshly prepared aqueous solutions, but be-
come dominant when standing at room temperature for 
many hours as it was also described for amoxycillin penicil-
loic acid [8]. Isocratic separation of all compounds within 10 
minutes, as seen in Fig. 1, was enabled by application of re-
versed phase ion pair chromatography. For LiChrospher R P 
18 silica a good compromise between separation of mezlocil-
l in and its degradation products from interfer.ng plasma 
components, and run time was found with 255 mg/1 tetra-
butylammonium hydrogensulfate in the mobile phase and 
p H 6.2. For Novapak C-18 silica a lower content of tetra-
butylammonium hydrogen sulfate (150 mg/1) and a higher 
p H (7.3) proved to give better resolution (see Materials and 
methods for more details). As metabolite of mezlocillin in 
plasma and urine, we found mezlocil l in penicilloic acid 
only. Since it has two carboxylic groups, the retention time 
is more sensitive to changes in concentration of tetrabutyl-
ammonium salt and p H than that of mezlocil l in hself. 
Fig . 2 shows chromatograms of a standard mixture of piper-
aci l l in and piperacill in penicilloic acid, prepared by incuba-
tion of piperacillin with ^-lactamase, and of plasma samples 
of a volunteer after injection of 4 g piperacill in. Like penicil-
loic acid derived from mezloci l l in , piperacillin penicilloic 
acid elutes as two separated epimers, and is hardly to deter-
mine in plasma. O n the other hand, two higher unidentified 
peaks appear at shorter retention times. 
3.2. Evaluation of the assay 
The chromatographic peaks were quantitated by the area 
method. The areas of the two unidentified metabolites of p i -
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Fig. 2: Chromatograms of (1) an aqueous standard solution of piperaci l l in (PIP, 250 ng) and piperaci l l in penici l loic acid ( P P C , ca. 200 ng mixture of epimers A 
and B ; the asterisk marks an impuri ty , presumably a hydrolysis product of piperacill in), (2) a plasma blank, (3) plasma o f a volunteer 1 h and (4) 4 h after the 
end of an intravenous infusion (30 min) of 4 g p iperac i l l in . X marks two unidentified peaks ( A and B), probably a mixture of epimers. concentrations: (3) P IP = 
47 ßg/ml P P C = 2,3 / i g / m l , X = 9,8 #g/ml when quantified as PIP. (4) PIP = 2,6 / / g / m l ; X = 4,8 ^ g / m l . Chromatographic condi t ions : see Mater ia l and meth-
ods. A U = absorption units. 
peraci l l in were summarized and quantified as piperacillin. 
The recovery from plasma was 101.1 ± 1.3% for mezlocillin 
(concentration 100 /ag/ml: n = 9), for mezlocil l in penicilloic 
acid 1100 .8±2 .8% (concentration 42 / i g /ml ; n = 9), for piper-
acillim 104.3 ± 4 . 0 (concentration 50 ^ g / m l ; n = 15) and for 
piperaci l l in penicil loic acid 91 to 93% (concentration 20 
/ ig/m.l ; n = 3). The recovery from urine was not checked and 
set 100%, as the only sample treatment step was dilution of 
urine with buffer. 
Some plasma specimens o f the mezloci l l in study were deter-
mined at two different days and the following reproducibility 
was found: mezloci l l in 102.7 =b4.8% (concentration range 
3.95 to 328 ywg/ml), mezloc i l l in penicilloic acid 1 0 7 ± 2 0 % 
(concentration range 0.80 to 3.6 //g/ml). The precision of the 
piperaci l l in assay was checked with spiked plasma. The re-
sults are shown in Table 1. 
3.3. Pharmacokinetics 
Fig. .3 and 5 show the mean ( ± S D ) plasma concentrations 
and the cumulative urinary excretion of mezlocill in and its 
ring-open metabolite, Fig. 4 and 6 the respective data of p i -
peracil l in. In addition, the plasma concentrations of ioxita-
lamic acid are depicted. In both cases, the mean plasma 
concentrations of the metabolites were always by far lower 
than the values of the respective parent compounds. Appar-
Table 1: Precision of the determinat ion o f piperaci l l in in plasma. (Piperacil-
l in added: 25, 5, 0.5 / /g/ml.) 
D a y Piperac i l l in (//g/ml) 
1 25.2 5.69 0.60 
2 26.0 5.85 0.69 
3 25.3 5.29 0.62 
4 26.1 5.96 0.69 
5 26.2 5.74 0.70 
M e a n 25.8 5.71 0.66 
S D (%) 0.5(1.8%) 0.25 (4.5%) 0.05 (7.0%) 
ently neither mezloci l l in nor piperacillin is metabolized in 
vivo to a greater extent. These findings are also illustrated in 
Table 2. In both studies we found nearly identical values for 
ioxitalamic acid in plasma, and in the beginning also for 
mezlocil l in and piperacill in. Wi th the time elapsed, the 
concentrations of mezlocil l in remained slightly higher than 
those of piperacil l in. 
The pharmacokinetic parameters of mezlocil l in, piperacil-
l in , and of ioxitalamic acid are summarized in Table 3. A l l 
substances exhibit distribution volumes nearly 20% of body 
weight which agrees good with the extracellular space. Like 
iotalamic acid [9], ioxitalamic acid shows the same plasma 
clearance as inulin (ca. 120 ml/min) , whereas those of mez-
loci l l in and piperacill in are about 250 ml /min . On the other 
hand, the half-life of ioxitalamic acid in plasma is about 2 h, 
whereas the half-lives of both antibiotics are 1 h. The uri-
nary recovery of ioxitalamic acid within 24 h was 90% in 
each study so that complete 24-h urine collection can be as-
sumed. A l s o the excretion of creatinine was normal in all 
subjects. About 50% of the antibiotic doses given were reco-
vered in the urine as active parent compounds, and 9% as 
metabolites in the case of piperacillin and 4% in the case 
of mezloci l l in. 
4. Discussion 
4.1. Chromatographic assay 
Besides the traditional bioassay, mezlocil l in and piperacillin 
have been also determined in biological fluids by reversed 
phase H P L C [10-15]. But in all these cases the parent com-
pounds only were assayed, as the ring-open metabolites are 
much more polar and elute with the front. Using gradient 
elution technique mezlocil l in [16], azloci l l in [17], apalcil l in 
[18], and the respective penicilloic acids could be deter-
mined simultaneously in serum and urine. Unfortunately, 
all assays are considerably time consuming. In the present 
assay incorporation of ion-pair chromatography enabled iso-
Table 2: Mean ( ± SD) concentrations o f mezloci l l in and piperaci l l in after infusion (30 min) of 4 g. and of simultaneously administered ioxitalamic acid (2.4 g) 
in plasma often healthy volunteers. I T X p i p = ioxitalamic acid in the piperacil l in study: I T X m e z = ioxi talamic acid in the mezloci l l in study; M E Z = mezloc i l -
lin ; P I P = piperaci l l in . 
T i m e 
I T X p i p 
(/ig/ml) 
I T X m e z 
Gwg/ml) 
I T X m e z 
I T X p i p 
M E Z 
(jug/ml) 
PIP 
(A*g/ml) 
M E Z 
100 (%) 
PIP 
- 1 5 m i n 1 ' 141 ± 2 7 134 ± 4 0 95.0 200 ± 58 198 ± 4 2 110.0 
0 min 2 » 194 ± 5 1 187 ± 4 5 96.4 271 ± 6 1 272 ± 7 5 99.6 
10 m i n 142 ± 1 8 144 ± 3 5 101.4 198 ± 4 6 187 ± 3 3 105.9 
20 m i n 126 ± 1 6 121 ± 2 7 104.3 158 ± 3 9 148 ± 2 6 106.8 
30 m i n 110 ± 1 5 108 ± 2 4 98.2 129 ± 3 4 118 ± 2 6 109.3 
45 m i n 94.9 ± 15.9 9 1 . 3 ± 1 7 . 9 96.2 9 7 . 7 ± 2 5 . 8 8 7 . 7 ± 2 2 . 5 111.4 
60 m i n 79.5 rt 11.5 7 8 . 5 ± 16.0 98.7 7 3 . 0 ± 2 1 . 8 6 5 . 2 ± 1 4 . 5 112.0 
90 m i n 6 2 . 5 ± 9.9 6 I . 0 ± 1 2 . 2 97.6 45.1 ± 1 6 . 5 3 9 . 6 ± 1 1 . 2 113.9 
2 h 49.3 ± 9.9 4 9 . 2 ± 10.8 99.8 2 9 . 5 ± 1 3 . 4 24.1 ± 8.4 122.4 
3 h 3 2 . 0 ± 8.2 3 2 . 0 ± 7.5 100.0 1 2 . 5 ± 4.7 I 1 . 5 ± 5.8 108.7 
4 h 22.1 ± 6.0 21.1 ± 6.9 95.5 6.0 ± 2.4 5 . 5 ± 3.1 109.1 
6 h 1 0 . 4 ± 3.0 9 . 6 ± 3.9 92.3 1 .6± 0.8 1.5± 0.6 106.7 
8 h 5.1 ± 2.3 5 . 0 ± 2.4 98.0 0.6 ± 0.4 0 . 6 ± 0.2 100.0 
Mean ± S D 9 8 . 0 ± 3 . 1 1 0 8 . 2 ± 6 . 2 
1 ' 15 min after the start of infusion (the antibiotics were infused at a constant rate over 30 min). 
2 ) At the end of infusion. 
Table 3 : Comparat ive pharmacokinet ic parameters (mean ± SD) of mezloci l l in (4 g), p iperaci l l in (4 g), and simultaneously administered ioxitalamic acid 
(2.4 g) given as short intravenous infusion (30 min) to 10 healthy volunteers. Abbreviat ions: I T X m e z = ioxi talamic acid in the mezloc i l l in test; I T X p i p = ioxita-
lamic acid in the piperacil l in test; M E Z = mez loc i l l i n ; PIP = piperac i l l in : Vss = steady-state volume of dis t r ibut ion: A U C = area under the plasma concentra-
tion-time curve; Cl t = total body clearance: iß - terminal plasma half-life; Vss% b.w. = Vss in percentage o f body weight; Clt 70 kg = Clt normalized to 70 kg 
body weight; Uo -24 h = 24-h urinary recovery. 
Vss Vss% b.w. A U C Clt C l t 7 0 kg Uo-24 h]) 
(1) (%) (mg/1 h) (ml/min) (ml /min /70 kg) (min) (% of dose) 
I T X m e z 15.5 ± 3.2 2 3 . 5 ± 3 . 6 3 4 9 ± 7 1 1 1 8 ± 2 2 1 2 7 ± 2 7 106 ± 1 5 93.1 ± 7.1 
I T X p i p 15 + ? 6 2 3 . 3 ± 4 . 5 359 ± 5 9 1 I 4 ± 1 8 1 2 3 ± 2 7 107 ± 1 4 8 7 . 2 ± 1 1 . 4 
M E Z 14.3 + 3.8 21.8 + 5.1 303 ± 7 6 231 ± 5 0 247 ± 5 2 6 3 . 9 ± 1 1 . 0 4 9 . 6 ± 4.7
2) 
PIP 1 4 . 5 ± 2 . 7 2 2 . 2 ± 4 . 7 2 8 2 ± 6 l 246 ± 5 0 262 ± 5 4 6 6 . 4 ± 1 3 . 0 4 9 . 6 ± 3.8
3) 
') 24-h creatinine excretion: mez loc i l l in study (1801 ± 5 3 0 mg (male): 1 2 1 5 ± 6 0 9 (female)). P iperac i l l in study ( 2 1 0 2 ± 130 mg (male). 1 3 0 9 ± 4 1 2 (female)). 
2> In addit ion: 4.1 ± 1.0% as mez loc i l l in penici l loic acid. 
3» In addition: 4 . 2 ± 0 . 7 % as piperaci l l in penici l loic acid, and 5 . 0 ± 1.5% as compound X . 
cratic determination of mezlocil l in, piperacil l in, and their 
probable main metabolites within 10 min at a moderate flow 
rate. 
From the present investigation it results that mezloci l l in and 
piperacillin are degraded only to a very small extent to the 
respective penicilloic acids after intravenous injection (Fig. 
3 and 4). Moreover, it seems doubtful whether the measured 
concentrations of the penicilloic acids are caused by enzy-
matic metabolization, or mainly by mere chemical hydroly-
sis. The instability of these and other penicillins in standing 
plasma specimens was several times reported, and even at 
-18 °C 20% degradation of mezlocil l in in plasma within 6 
weeks was observed, whereby half of it was found in form of 
mezlocil l in penicilloic acid [3]. Therefore, the detection of 
large amounts of mezlocil l in penicilloic acid in any body 
fluid specimen may indicate rather in vitro degradation of 
the parent compound than in vivo metabolism. In such 
cases, false low concentrations of mezlocil l in are measured, 
and determination of degradation products can prove it (cf. 
[3]). In accordance with results examined by G a u and För-
ster [16] we did not find mezlocil l in penilloic acid in plas-
ma and urine, and indeed, the detection of penilloic acid in 
body fluids [19] may have been an artefact of the analytical 
procedure [3]. 
Even quantitative disappearance of piperacill in from plasma 
specimens was stated when stored for several weeks at 
- 2 0 °C ([10]; unfortunately, though H P L C was used, no at-
tempt was made to look for degradation products). O n the 
other hand, at - 7 0 °C both antibiotics proved to be stable [3, 
10]. 
In our study, al l specimens were stored at - 7 0 °C no longer 
than 7 weeks so that stability of piperacill in should be guar-
anteed. Moreover, we found only small amounts of piper-
aci l l in penicilloic acid, the supposed main degradation pro-
duct in stored plasma. But beyond that, two unidentified sig-
nals appeared in the chromatograms of plasma and urine 
(Fig. 2, chromatograms 3 and 4, peaks X - A and X - B ) . 
O n following reasons we believe the signals may refer to 
6- [D- (-)-a- {3- [2- ( N - ethyl-N-oxalamino) ethyl] ureido}-#-
phenylacetamido] penicilloic acid (Scheme 1), denoted X in 
Fig. 1, which is partially epimerized at the carbon atom in 
position 5, and elutes therefore as two distinct peaks. First, 
the peak/height ratio 229 to 254 nm (Fig. 2) of X - A and X - B 
is similar to those of piperacillin and piperacill in penicilloic 
acid which fits the proposed structure. Second, with time the 
relative amount of the faster eluting peak increases in 
accordance with findings in the case of the penicil loic acids 
of mezlocil l in and apalcill in ([18]; unfortunately, piperacil-
l in penicilloic acid was hardly to quantify in plasma, all the 
more since the isomer A was often covered by an endoge-
nous compound). Thi rd , the same splitting of the dioxopi-
perazine ring was foundi in the case of cefoperazone [20]. 
The Baternan-function-like concentration-time course of 
compound X in plasma (Fig. 4) demonstrates it to be formed 
in vivo, presumably as a metabolite of piperacill in penicil-
loic acid. However, the identity of the compounds X - A and 
X - B remains to be elucidated. 
4.2. Comparative pharmacokinetics of mezlocillin and 
piperacillin 
The study was not designed in a randomised cross-over fash-
ion but the analysis of the pharmacokinetic parameters of 
ioxitalamic acid in both tests (Table 3) revealed nearly iden-
tical mean values so that similar conditions can be assumed 
to exist for both antibiotics mezlocill in and piperacil l in. A l l 
their mean pharmacokinetic parameters differed not more 
than 10% from each other which is within the analytical er-
ror, and in accordance with published data [21, 22]. W e ob-
served also the same urinary recovery of both antibiotics, 
about half of the dose given, which was to be expected for 
mezlocil l in only [3, 16, 21]. Tjandramaga [22] found 80% of 
piperacill in in the urine when a 4 g intravenous dose was 
given. This is in clear contrast to our results. O n the other 
hand, a range of 40 -70% renal excretion of piperacill in is 
also reported (cf. [23, 24]). So, for piperacillin a very varia-
ble range of renal excretion is found. Our data are at its 
lower margin, but in good agreement with the renal excre-
tion of the other acylureido penicillins, mezlocil l in [3. 16, 
21] and azloci l l in [17], which exhibit very similar chemical 
structures. 
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